Genmab A/S Files Routine 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, routine-filing, registration-statement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K, just procedural stuff, no new news.
AI Summary
Genmab A/S filed a Form 6-K on September 10, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing is routine and does not contain specific financial updates or material events.
Why It Matters
This filing serves to incorporate information into existing SEC filings, which is a standard procedural step for companies with ongoing registration statements.
Risk Assessment
Risk Level: low — The filing is a routine administrative submission and does not disclose new material information or risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-012700 (filing_id) — Accession Number
- 20240910 (date) — Filing Date
- Form 6-K (document_type) — Filing Type
- Form S-8 (document_type) — Incorporated by Reference
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8.
What is the filing date of this report?
This report was filed on September 10, 2024.
Which SEC registration statements will this filing be incorporated into?
This filing will be incorporated into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Is Genmab A/S a foreign private issuer?
Yes, the filing is a 'REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934'.
What is the principal executive office address for Genmab A/S?
The principal executive office address is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-09-10 16:16:27
Filing Documents
- tmb-20240910x6k.htm (6-K) — 18KB
- tmb-20240910xex99d1.htm (EX-99.1) — 24KB
- tmb-20240910xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-012700.txt ( ) — 50KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: SEPTEMBER 10, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated September 10, 2024: Capital Increase in Genmab as a Result of Employee Warrant Exercise